scholarly journals Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients

1999 ◽  
Vol 24 (9) ◽  
pp. 971-979 ◽  
Author(s):  
G Benedetti ◽  
L Patoia ◽  
A Giglietti ◽  
M Alessio ◽  
PG Pelicci ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Progenitor Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
High Dose ◽  
Severe Thrombocytopenia ◽  
Breast Cancer Patients ◽  
Peripheral Blood Progenitor Cells ◽  
High Dose Melphalan

scholarly journals Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients

2001 ◽  
Vol 12 (4) ◽  
pp. 505-508 ◽  
Author(s):  
L. Del Mastro ◽  
M. Venturini ◽  
C. Viscoli ◽  
M. Bergaglio ◽  
A. Signorini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progenitor Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Cancer Patients ◽  
Peripheral Blood Progenitor Cells ◽  
Intensified Chemotherapy

Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.

1994 ◽  
Vol 12 (1) ◽  
pp. 28-36 ◽  
Author(s):  
E J Shpall ◽  
R B Jones ◽  
S I Bearman ◽  
W A Franklin ◽  
P G Archer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Positive Selection ◽  
Progenitor Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Colony Stimulating Factor ◽  
Breast Cancer Patients ◽  
Stimulating Factor

PURPOSE To evaluate the capacity of enriched CD34-positive (CD34+) progenitor cells to reconstitute hematopoiesis in poor-prognosis breast cancer patients following administration of a high-dose alkylating agent chemotherapy regimen. PATIENTS AND METHODS Forty-four breast cancer patients received high-dose chemotherapy followed by autologous bone marrow support (ABMS) with CD34+ hematopoietic progenitor cells in five sequentially treated cohorts. Following infusion of CD34+ marrow, cohort no. 1 received no growth factor, cohort no. 2 received granulocyte colony-stimulating factor (G-CSF), and cohort no. 3 received granulocyte-macrophage colony-stimulating factor (GM-CSF). Cohort no. 4 received the CD34+ fractions of both marrow and peripheral-blood progenitor cells (PBPCs) plus G-CSF. Cohort no. 5 received only the CD34+ PBPCs plus G-CSF. Immunohistochemical staining for breast cancer was performed on all hematopoietic cell products before and after the positive selection procedure, to assess quantitatively the level of tumor-cell contamination. RESULTS Cohorts no. 1, 2, 3, 4, and 5 achieved a granulocyte count > or = 500 x 10(9)/L in a median of 23, 10, 16, 11, and 11 days, with a platelet count greater than 20,000 x 10(9)/L documented in a median of 22, 23, 32, 12, and 10 days, respectively. The time to granulocyte reconstitution was significantly shorter for patients who received CD34+ PBPCs alone (cohort no. 5), or in combination with CD34+ marrow (cohort no. 4), when compared with those who received only the CD34+ marrow fraction (P < .01). From 1 to greater than 4 logs of breast cancer cell depletion were documented after CD34-selection, for patients in whom tumor was initially detected. CONCLUSION CD34+ marrow and/or PBPCs provide reliable and timely hematopoietic reconstitution in breast cancer patients receiving high-dose chemotherapy. Contamination of both marrow and PBPCs with breast cancer cells was reduced using this positive selection technique.

scholarly journals Epirubicin + G-CSF as peripheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients

1995 ◽  
Vol 6 (10) ◽  
pp. 1045-1047 ◽  
Author(s):  
G. Rosti ◽  
L. Albertazzi ◽  
P. Ferrante ◽  
P. Nicoletti ◽  
P. Morandi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progenitor Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Cancer Patients ◽  
Peripheral Blood Progenitor Cells

Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer

Blood ◽  
2000 ◽  
Vol 96 (9) ◽  
pp. 3001-3007 ◽  
Author(s):  
Ian McNiece ◽  
Roy Jones ◽  
Scott I. Bearman ◽  
Pablo Cagnoni ◽  
Yago Nieto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progenitor Cells ◽  
Peripheral Blood ◽  
Ex Vivo ◽  
High Dose Chemotherapy ◽  
Control Group ◽  
High Dose ◽  
Platelet Recovery ◽  
Peripheral Blood Progenitor Cells ◽  
Neutrophil Engraftment

Abstract Ex vivo expanded peripheral blood progenitor cells (PBPCs) have been proposed as a source of hematopoietic support to decrease or eliminate the period of neutropenia after high-dose chemotherapy. CD34 cells were selected from rhG-CSF mobilized PBPCs from patients with breast cancer and were cultured for 10 days in defined media containing 100 ng/mL each of rhSCF, rhG-CSF, and PEG-rhMGDF in 1 L Teflon bags at 20 000 cells/mL. After culture the cells were washed and reinfused on day 0 of transplantation. On day +1, cohort 1 patients (n = 10) also received an unexpanded CD34-selected PBPC product. These patients engrafted neutrophils (absolute neutrophil count, &gt;500/μL) in a median of 6 (range, 5-14) days. Cohort 2 patients (n = 11), who received expanded PBPCs only, engrafted neutrophils in a median of 8 (range, 4-16) days. In comparison, the median time to neutrophil engraftment in a historical control group of patients (n = 100) was 9 days (range, 7-30 days). All surviving patients are now past the 15-month posttransplantation stage with no evidence of late graft failure. The total number of nucleated cells harvested after expansion culture was shown to be the best predictor of time to neutrophil engraftment, with all patients receiving more than 4 × 107 cells/kg, engrafting neutrophils by day 8. No significant effect on platelet recovery was observed in any patient. These data demonstrate that PBPCs expanded under the conditions defined can shorten the time to engraftment of neutrophils compared with historical controls and that the rate of engraftment is related to the dose of expanded cells transplanted.

Sign in / Sign up

Export Citation Format

Share Document